Eosinophilic Esophagitis is a chronic, allergic inflammatory disease characterised by eosinophilic infiltration of the esophagus, which can lead to inflammation and ultimately strictures and narrowing of the esophagus, putting patients at risk of food impaction.
APT-1011 is a novel formulation incorporating Adare's proprietary AdvaTab technology is and the only fluticasone product in advanced clinical development for EoE.
Currently, there are no FDA approved EoE treatments available in the US.
The FLUTE trial is designed to measure the efficacy and safety of a number of doses of APT-1011 in more than 100 patients identified as having EoE and to advance Adare's proprietary patient reported outcome tool PROSE for EoE.
The study results indicate that the primary end-point was achieved, as were a number of secondary endpoints that measured patient symptoms and improvement of characteristic features of the disease. The product was found to be well tolerated at all doses tested.
Significant progress was also achieved in the development of PROSE. The FLUTE study, will continue in 2019 and will characterise the persistence of treatment effect. The company anticipates initiation of its Phase 3 program in the second half of 2019.
The FLUTE study is part of Adare Pharmaceuticals HARMONY Clinical Trial programme, which is focused on the development of APT-1011 in eosinophilic esophagitis in adults, adolescents and children.
APT-1011 is a novel, oral formulation of fluticasone incorporating Adare's proprietary AdvaTab technology that allows for topical delivery of the drug to the esophagus whilst minimizing residence time in the oral cavity.
In earlier clinical trials, APT-1011 was shown to be effective in reducing esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. APT-1011 has received orphan drug designation from the FDA and EMA.
Eosinophilic Esophagitis or "EoE" is a chronic and rare disease. EoE prevalence rate in the US is estimated at 57 in 100,000 (Dellon E et al. 2014) and is evolving due to increasing awareness of the disease.
The exact cause of EoE is unknown, however it is believed to be triggered by a variety of stimuli, including certain foods and environmental allergens.
Symptoms of EoE in adults include dysphagia (difficulty or discomfort in swallowing) and, in severe cases, food impaction (obstruction of the esophagus by food) and strictures (narrowing of the esophagus due to scar tissue formation). Early diagnosis and treatment of EoE is important to prevent progression to fibrotic changes in the esophagus which may be only partially reversible.
Current management of EoE includes, food elimination diets, off-label use of proton pump inhibitors and glucocorticoid steroid formulations. Currently in the United States, there are no therapeutic products approved for the treatment of EoE.
Adare Pharmaceuticals utilises its differentiated Pharmaceutical Technology and Microbiome scientific platforms to develop novel value-added products for the global market.
Through its Specialty CDMO business, Adare provides co-development and contract services to biopharmaceutical companies to develop and manufacture products that are marketed by its partners. Through its Adare Development affiliate, Adare invests in its own product pipeline and currently has a number of investigational products in various stages of development.
Adare has developed and manufactured more than 40 products sold by partners in more than 100 countries globally including Lacteol, Zoolac, Viactiv, Amrix and a number of branded and complex generic products.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling